{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T14:52:00Z","timestamp":1772463120278,"version":"3.50.1"},"reference-count":115,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":4705,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[1999,3]]},"abstract":"<jats:p>Protease inhibitors (PIs) effectively inhibit replication of the human immunodeficiency virus (HIV), and reduce mortality and prolong survival in patients with HIV infection. Newer PIs saquinavir (soft gelatin capsule) and amprenavir, as well as other PIs, may be effective when administered twice\/day. Adverse reactions may occur, as well as metabolic complications and interactions between PIs and other drugs, including other PIs. The strategy of combining PIs is based on specific pharmacologic interactions among the agents.<\/jats:p>","DOI":"10.1592\/phco.19.4.281.30937","type":"journal-article","created":{"date-parts":[[2004,4,27]],"date-time":"2004-04-27T10:55:45Z","timestamp":1083063345000},"page":"281-298","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["HIV Protease Inhibitors: Advances in Therapy and Adverse Reactions, Including Metabolic Complications"],"prefix":"10.1002","volume":"19","author":[{"given":"Daniel R.","family":"Kaul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro K.","family":"Cinti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy L.","family":"Carver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Powel H.","family":"Kazanjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709113371101"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)04161-5"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709113371102"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.1.78"},{"key":"e_1_2_1_6_2","first-page":"RR\u20105","article-title":"Report of the NIH panel on principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV\u2010infected adults and adolescents","volume":"47","year":"1998","journal-title":"MMWR"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.13.4686"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/515312"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610103351501"},{"key":"e_1_2_1_10_2","first-page":"3","volume-title":"Ambulatory care of the HIV\u2010infected patient","author":"Kazanjian P.","year":"1997"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.272.5265.1167"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_1_13_2","volume-title":"Fortovase (saquinavir soft gel caps) package insert","author":"Pharmaceuticals Roche","year":"1997"},{"key":"e_1_2_1_14_2","unstructured":"SlaterL..Activity of a new formulation of saquinavir in combination with two nucleosides in treatment na\u00efve patients [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_15_2","unstructured":"BorleffsJC.First comparative study of saquinavir soft gel capsules vs. indinavir as part of triple therapy regimen (CHEESE) [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_16_2","unstructured":"SensionM. FarthingC. PattisonTP PilsonR. Siemon\u2010HryczykP..Fortovase (saquinavir soft gel capsule; SQV\u2010SGC) in combination with AZT and 3TC in antiretroviral\u2010na\u00efve HIV\u20101 infected patients [abstr]. In: Programs and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_17_2","unstructured":"SchooleyR..Preliminary data on the safety and antiviral efficacy of the novel protease inhibitor 141W94 in HIV\u2010infected patients with 150 to 400 CD4 cells\/mm3 [abstr]. In: abstracts of the 36th interscience conference on antimicrobial agents and chemotherapy New Orleans September 1518 1996."},{"key":"e_1_2_1_18_2","unstructured":"BartPA RizzardiGP GallanS. et al.Combination 1592\/141W94 therapy in HIV\u20101\u2010infected antiretroviral na\u00efve subjects with CD4+ counts >400 cells\/\u03bcl and viral load > 5000 copies\/ml [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_19_2","unstructured":"HaubrichR..Phase 2 study of amprenavir a novel protease inhibitor in combination with zidovudine\/3TC [abstr]. In: Conference record of the 12th World AIDS Conference Geneva June 28July 3 1998."},{"key":"e_1_2_1_20_2","unstructured":"EronJ. HaubrichR. RichmanD. et al.Preliminary assessment of 141W94 in combination with other protease inhibitors [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_21_2","volume-title":"Compound 141W94 general information","author":"Wellcome Glaxo","year":"1998"},{"key":"e_1_2_1_22_2","unstructured":"NguyenBY HaasDW Ramirez\u2010RondaC. et al.Thirty two week follow up of indinavir sulfate administered Q8 hours versus Q12 hours in combination with zidovudine and lamivudine [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_23_2","unstructured":"Indinavir (Crixivan) alert! 1998 Project Inform"},{"key":"e_1_2_1_24_2","volume-title":"Crixivan (indinavir) drug information","author":"Merck and Co","year":"1997"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199712000-00002"},{"key":"e_1_2_1_26_2","volume-title":"Viracept (nelfinavir) prescribing information","year":"1997"},{"key":"e_1_2_1_27_2","unstructured":"SensionM. ElionR. FarthingC. et al.Open label pilot studies to assess the safety and efficacy of bid dosing regimens of Viracept (nelfinavir mesylate) combined with NRTIs in HIV\u2010infected treatment\u2010na\u00efve patients [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_28_2","unstructured":"JohnsonM. PetersenA. WinsladeJ. ClendeninnN..Comparison of bid and tid dosing of Viracept (nelfinavir NFV) in combination with stavudine (d4T) and lamivudine (3TC) [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_29_2","unstructured":"CohenC. Siemon\u2010HryczykP. PilsonR. et al.Potent and convenient Fortovase BID regimens in combination with two nucleosides or nelfinavir plus one nucleoside in HIV\u20101 infected patients [abstr]. In: Conference record of the 12th World AIDS Conference Geneva June 29July 3 1988."},{"key":"e_1_2_1_30_2","volume-title":"Norvir (ritonavir) drug information","author":"Abbott Laboratories","year":"1997"},{"key":"e_1_2_1_31_2","volume-title":"Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus","author":"Lumpkin MM","year":"1997"},{"key":"e_1_2_1_32_2","unstructured":"DongBJ GrutaC. LeggJ. BalanoRH GoldschimdtRH.Diabetes and use of protease inhibitors [abstr]. In: Programs and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)63513-1"},{"key":"e_1_2_1_34_2","unstructured":"KerulyJC ChaissonRE MooreRD.Diabetes and hyperglycemia in patients receiving protease inhibitors [abstr]. In: Programs and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00003"},{"key":"e_1_2_1_36_2","unstructured":"MulliganK. TaiVW AlgrenH. et al.Evidence of unique metabolic effects of protease inhibitors [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_37_2","doi-asserted-by":"crossref","unstructured":"WalliRK HerfortO. MichlGM et al.Peripheral insulin resistance leading to impaired glucose tolerance in HIV\u20101 infected patients treated with protease inhibitors. In: Conference record of the 12th World AIDS Conference Geneva June 28 July 3 1998.","DOI":"10.1097\/00002030-199815000-00001"},{"key":"e_1_2_1_38_2","unstructured":"RothVR AngelJB KravcikS..Development of a cervical fat pad following treatment with HIV\u20101 protease inhibitors [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_39_2","unstructured":"HengelRL GearyJAM VuchetichMA et al.Multiple symmetrical lipomatosis associated with protease inhibitor therapy [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11443-X"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199806000-00001"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11518-5"},{"key":"e_1_2_1_43_2","unstructured":"DongK. FlynnMM DickinsonBP et al.Changes in body habitus in HIV(+) women after initiation of protease inhibitor therapy [abstr]. In: Conference record of the 12th World AIDS Conference Geneva June 28July 3 1998."},{"key":"e_1_2_1_44_2","unstructured":"CameronDW JapourA. MellorsC. et al.Antiretroviral safety and durability of ritonavir\u2010saquinavir in protease inhibitor naive patients in year two of follow\u2010up (abstr]. In: Programs and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)79053-X"},{"key":"e_1_2_1_46_2","unstructured":"RobertsAD MuesingRA ParentiDM HsiaJ. WassermanAG SimonGL.Alterations in serum lipids and lipoproteins with indinavir in HIV\u2010infected patients. Presented at the 35th annual meeting of the Infectious Disease Society of America San Francisco September 1316 1997."},{"key":"e_1_2_1_47_2","unstructured":"BernasconeE. CarotaA. MagentaL. PonsM. RussottiM. MoccettiT..Metabolic changes in HIV\u2010infected patients treated with protease inhibitors [abstr]. In: Conference record of the 12th World AIDS Conference Geneva June 28July 3 1998."},{"key":"e_1_2_1_48_2","unstructured":"HenryK..Lipid abnormalities associated with use of protease inhibitors: prevalence clinical sequelae and treatment [abstr]. In: Conference record of the 12th World AIDS Conference Geneva June 28\u2013July 3."},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-2-199707150-00004"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701093360215"},{"key":"e_1_2_1_51_2","first-page":"388","article-title":"Unusual occurrence of spontaneous hematomas in three asymptomatic HIV\u2010infected haemophilia patients a few days after the onset of ritonavir treatment","volume":"11","author":"Ginsburg C.","year":"1997","journal-title":"AIDS"},{"issue":"1","key":"e_1_2_1_52_2","first-page":"90","article-title":"HIV protease inhibitors and increased bleeding in hemophilia?","volume":"156","author":"Helal A.","year":"1997","journal-title":"Can Med Assoc J"},{"key":"e_1_2_1_53_2","unstructured":"FeigalDW.FDA letter to health care providers: HIV protease inhibitors and hemophiliac patients.July 16 1996."},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1997.t01-1-00098.x"},{"key":"e_1_2_1_55_2","unstructured":"RuizI. AltisentC. OcanaI. et al.Indinavir in therapy\u2010experienced HIV haemophiliac patients [abstr]. Presented at the 6th European conference on clinical aspects and treatment of HIV infection Hamburg Germany October 1115 1997."},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199801010-00007"},{"key":"e_1_2_1_57_2","volume-title":"Glucophage (metformin) package insert","author":"Squibb Bristol\u2010Myers","year":"1996"},{"key":"e_1_2_1_58_2","volume-title":"Precose (acarbose) package insert","author":"Bayer Corporation","year":"1996"},{"key":"e_1_2_1_59_2","volume-title":"Rezulin (troglitazone) package insert","author":"Warner\u2010Lambert","year":"1997"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)90225-8"},{"issue":"5","key":"e_1_2_1_61_2","first-page":"333","article-title":"The prognostic value of plasma triglycerides in HIV infections","volume":"147","author":"Rovira E.","year":"1996","journal-title":"Ann Med Interne (Paris)"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199307000-00022"},{"key":"e_1_2_1_63_2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/jn\/122.suppl_3.749","article-title":"The role of the cytokines interferon alpha and tumor necrosis factor in the hypertriglyceridemia and wasting of AIDS","volume":"122","author":"Grunfeld C.","year":"1992","journal-title":"J Nutr"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.76.6.1423"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113046"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-125-1-267"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198711123172001"},{"key":"e_1_2_1_68_2","volume-title":"Lopid (gemfibrozil) package insert","author":"Warner\u2010Lambert","year":"1996"},{"issue":"5","key":"e_1_2_1_69_2","first-page":"32","article-title":"Atorvastatin: a potent new HMG\u2010CoA reductase inhibitor","volume":"19","author":"Hilleman DE","year":"1998","journal-title":"Cardiovasc Rev Rep"},{"key":"e_1_2_1_70_2","volume-title":"Lipitor (atorvastatin) package insert","author":"Warner\u2010Lambert","year":"1996"},{"issue":"9","key":"e_1_2_1_71_2","first-page":"S347","article-title":"Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates: erythromycin and ethinyl estradiol [abstr]","volume":"13","author":"Yang B\u2010B","year":"1996","journal-title":"Pharm Res"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.5.971"},{"key":"e_1_2_1_73_2","first-page":"1329","article-title":"Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults","volume":"90","author":"National Cholesterol Education Program","year":"1994","journal-title":"Circulation."},{"key":"e_1_2_1_74_2","unstructured":"DuncombeC. BlochM. AustinD. QuanD..Reversal of hyperlipidemia and lipodystrophy in patients switching therapy to nelfinavir [abstr]. In: Conference record of the 12th World AIDS Conference Geneva June 28July 3 1998."},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03391-1"},{"key":"e_1_2_1_76_2","unstructured":"TorresR..Treatment of dorsocervical fat pads and truncal adiposity with serostim (recombinant human growth hormone) in patients with AIDS maintained on HAART [abstr]. In: Conference record of the 12th World AIDS Conference Geneva June 28July 3 1998."},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.12.930"},{"key":"e_1_2_1_78_2","unstructured":"StaszewskiS. Morales\u2010RamirezJ. FlaniganT. et al.A phase II multicenter randomized open\u2010label study to compare the antiretroviral activity and tolerability of efavirenz + indinavir versus efavirenz + zidovudine + lamivudine versus indinavir + zidovudine + lamivudine at 24 weeks [DMP 266\u2010006] [abstr]. In: Conference record of the 12th World AIDS Conference Geneva June 28July 3 1998."},{"key":"e_1_2_1_79_2","unstructured":"FischlM. GreenbergS. ClumeckN. et al.Safety and activity of abacavir (1592 ABC) with 3TC\/ZDV in antiretroviral na\u00efve subjects [abstr]. In: Conference record of the 12th World AIDS Conference Geneva June 28July 3 1998."},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.19.3.287"},{"key":"e_1_2_1_81_2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0090-9556(25)06651-6","article-title":"pH\u2010Dependent oral absorption of L\u2010734, 524, a potent HIV protease inhibitor, in rats and dogs","volume":"23","author":"Lin JH","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_82_2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0090-9556(25)06530-4","article-title":"Metabolites of L\u2010735,524, a potent HIV\u20101 protease inhibitor, in human urine","volume":"23","author":"Balani SH","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_83_2","unstructured":"PolkRE IsraelDS PastorA. et al.Pharmacokinetic interaction between 141W94 and rifabutin and rifampin after multiple\u2010dose administration [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90036-4"},{"key":"e_1_2_1_85_2","first-page":"20","article-title":"Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations","volume":"47","year":"1998","journal-title":"MMWR"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199528020-00003"},{"key":"e_1_2_1_87_2","unstructured":"SunE. Heath\u2010ChiozziM. CameronDW et al.Concurrent ritonavir and rifabutin increase risk of rifabutin\u2010associated adverse events [abstr]. In: Program and abstracts of the XI international conference on AIDS Vancouver Canada July 712 1996."},{"key":"e_1_2_1_88_2","unstructured":"MerryC. BarryMG MulcahyFM RyanM..BackDJ.The pharmacokinetics of nelfinavir alone and in combination with nevirapine [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_89_2","unstructured":"SkowronG. LeongG. DusekR. et al.Stavudine nelfinavir and nevirapine: preliminary safety activity and pharmacokinetic interactions [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_90_2","volume-title":"Rescriptor (delavirdine mesylate) product information","author":"Pharmacia","year":"1997"},{"key":"e_1_2_1_91_2","unstructured":"MorseGD SheltonMJ HewittRG et al.Ritonavir pharmacokinetics during combination therapy with delavirdine [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_92_2","unstructured":"CoxSR SchneckDW HermanBD et al.Delavirdine and nelfinavir: a pharmacokinetic drug interaction study in healthy adults volunteers [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_93_2","unstructured":"FiskeWD BendexLH WhiteSJ et al.Pharmacokinetic interaction between efavirenz and nelfinavir mesylate in healthy volunteers [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_94_2","unstructured":"FiskeWD MayersD. WagnerK. et al.Pharmacokinetics of DMP 266 and indinavir multiple oral doses in HIV\u20101 infected individuals [abstr]. In: Program and abstracts of the 4th conference of retroviruses and opportunistic infections Washington DC January 2226 1997."},{"key":"e_1_2_1_95_2","unstructured":"PiscitelliS. VogelS. SadlerBM et al.Effect of efavirenz (DMP 266) on the pharmacokinetics of 141W94 in HIV\u2010infected patients. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_96_2","volume-title":"Invirase (saquinavir hard gel capsules) drug information","author":"Roche Laboratories","year":"1997"},{"key":"e_1_2_1_97_2","unstructured":"PolkRE IsraelDS PastorA. et al.Pharmacokinetic interaction between ketoconazole and the HIV protease inhibitor 141W94 after a single dose administration to normal volunteers [abstr]. In: Abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy Toronto Canada September 28October 1 1997."},{"key":"e_1_2_1_98_2","unstructured":"OpravilM..Study of protease inhibitor combination in Europe (SPICE); saquinavir soft gel capsule (SQV\u2010SGC) and nelfinavir in HIV infected individuals [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_99_2","unstructured":"KravcikS. FarnsworthA. PatickA. et al.Long term follow\u2010up of combination protease inhibitor therapy with nelfinavir and saquinavir (soft gel) in HIV infection [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_100_2","unstructured":"BussN..Saquinavir soft gel capsule (Fortovase): pharmacokinetics and drug interactions [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_101_2","unstructured":"HsuA. GrannemanGR JapourA. CaoG. LockeC..Ritonavir and indinavir potential BID regimens [abstr]. In: Abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy Toronto Canada September 28October 1 1997."},{"key":"e_1_2_1_102_2","unstructured":"MerryC. DarryMG MulcahyF. BackDJ.Saquinavir pharmacokinetics alone and in combination with nelfinavir [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_103_2","unstructured":"GallicanoK. SahaiJ. KravcikS. SeguinI. BristowN. CameronDW.Nelfinavir (NFV) increases plasma exposure of saquinavir in hard gel capsule (SQV\u2010HGC) in HIV positive patients [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_104_2","unstructured":"GisolfE. ColebundersR. VanWanzeeleF. et al.Treatment ritonavir\/saquinavir versus ritonavir\/saquinavir\/stavudine [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_105_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199712000-00002"},{"key":"e_1_2_1_106_2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00002030-199806000-00011","article-title":"The antiviral effect of ritonavir and saquinavir in combination amongst HIV\u2010infected adults: results from a community\u2010based study","volume":"12","author":"Rhone S.","year":"1998","journal-title":"AIDS"},{"key":"e_1_2_1_107_2","unstructured":"GallantJE BarnettS. RainesC. HallC..Efficacy and durability of ritonavir\/saquinavir as salvage therapy after failure of initial protease inhibitor regimen [abstr]. In: Conference record of the 12th World AIDS Conference Geneva June 29July 3 1988."},{"key":"e_1_2_1_108_2","unstructured":"FarthingC. MessT. ReidC. RadhakrishnaS. WallaceM..Ritonavir saquinavir and nevirapine as a salvage regimen for indinavir or ritonavir resistance [abstr]. In: Conference record of the 12th World AIDS Conference Geneva June 28July 3 1998."},{"key":"e_1_2_1_109_2","unstructured":"RuanePJ TamJT LibratyDH SokolovRT UmanSJ ZakowskiPC.Salvage therapy using ritonavir\/saquinavir with a non\u2010nucleoside reverse transcriptase inhibitor after prolonged failure with indinavir or ritonavir [abstr]. In: Conference record of the 12th World AIDS Conference Geneva June 28July 3 1998."},{"key":"e_1_2_1_110_2","unstructured":"LallemandF. AddaN. SchneiderV. WirbelB. JacometC. RozenbaumW..Prospective follow\u2010up of 67 indinavir experienced HIV\/AIDS patients treated with ritonavir\/saquinavir combination [abstr]. In: Abstracts of the 38th international conference on antimicrobial agents and chemotherapy San Diego CA September 2327 1998."},{"key":"e_1_2_1_111_2","unstructured":"CohenC. Siemon\u2010HryczkP. PilsonR. et al.Potent and convenient Fortovase (SQV) SGC BID regimens in combination with 2 nucleosides or nelfinavir (NFV) plus 1 nucleoside in HIV\u20101 infected patients [abstr]. In: Conference record of the 12th World AIDS Conference Geneva June 28July 3 1998."},{"key":"e_1_2_1_112_2","unstructured":"LohmeyerJ. SelhorstJ. FrieseG. TeichmannJ. DischerT..Combined nelfinavir\/saquinavir protease inhibitor treatment in a BID regimen as salvage therapy in advanced HIV disease [abstr]. In: Conference record of the 12th World AIDS Conference Geneva June 28July 3 1998."},{"key":"e_1_2_1_113_2","unstructured":"DeeksS..Twenty\u2010week HIV RNA response and correlation with baseline phenotypic drug susceptibility during treatment with a novel quadruple salvage regimen after failure of indinavir combination therapy [abstr]. In: Conference record of the 12th World AIDS Conference Geneva June 28July 3 1998."},{"key":"e_1_2_1_114_2","unstructured":"HavlirDV RiddlerS. SquiresK. et al.Co\u2010administration of indinavir (IDV) and nelfinavir (NFV) in a twice daily regimen: preliminary safety pharmacokinetics and anti\u2010viral activity results [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_115_2","unstructured":"GallantJE Heath\u2010ChiozziM. RainesC. et al.Safety and efficacy of nelfinavir\u2010ritonavir combination therapy [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections Chicago February 15 1998."},{"key":"e_1_2_1_116_2","unstructured":"WorkmanC. MussonR. DyerW. SullivanJ..Novel double protease combinations combining indinavir (IDV) with ritonavir (RTV): results from first study [abstr]. In: Conference record of the 12th World AIDS Conference Geneva June 28July 3 1998."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.19.4.281.30937","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.19.4.281.30937","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:12:36Z","timestamp":1761052356000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.19.4.281.30937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,3]]},"references-count":115,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1999,3]]}},"alternative-id":["10.1592\/phco.19.4.281.30937"],"URL":"https:\/\/doi.org\/10.1592\/phco.19.4.281.30937","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,3]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}